Cover Image


Global Hodgkin's Lymphoma Treatment Market - Segmented by Treatment Type and Geography - Growth, Trends and Forecasts (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 546541
出版日期 內容資訊 英文 108 Pages
商品交期: 最快1-2個工作天內
Back to Top
何杰金氏淋巴瘤的治療方法的全球市場:成長率、趨勢、預測 Global Hodgkin's Lymphoma Treatment Market - Segmented by Treatment Type and Geography - Growth, Trends and Forecasts (2018 - 2023)
出版日期: 2018年02月08日 內容資訊: 英文 108 Pages

本報告提供何杰金氏淋巴瘤的各種治療方法、治療藥的市場相關分析,疾病概要和現在/未來可利用的治療選擇,主要的促進、阻礙因素,市場規模趨勢預測 (今後6年份),各領域、各地區的詳細趨勢,近幾年的市場競爭的動向,主要企業簡介等調查。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 主要考察事項

第5章 市場概要、產業趨勢

  • 目前市場方案
  • 市場概要
  • 波特的五力分析

第6章 推動、市場的阻礙要素/機會/課題分析 (DROC分析)

  • 市場的推動要素
  • 市場的阻礙要素
  • 市場機會
  • 主要課題

第7章 全球輸卵管癌症市場:各領域

  • 治療方法的種類
    • 手術
    • 化療
    • 放射治療

第8章 全球輸卵管癌症市場:各地區的市場規模、佔有率預測

  • 北美 (美國,加拿大,墨西哥)
  • 歐洲 (德國,英國,法國,義大利,西班牙、葡萄牙,北歐各國,荷比盧三國等)
  • 亞太地區 (中國,日本,印度,澳洲、紐西蘭,韓國等)
  • 中東、非洲 (波灣合作理事會 (GCC) 各國,南非等)
  • 南美 (巴西,阿根廷等)

第9章 競爭環境

  • 企業合併、收購 (M&A) 分析
  • 新產品的銷售
  • 協定,產業合作、聯盟

第10章 企業簡介

  • Amgen Inc.
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Celgene
  • Eli Lilly and Company
  • Roche
  • 其他

第11章 投資機會相關分析師的見解

第12章 市場未來展望


Product Code: 33713


The global Hodgkin's Lymphoma treatment market is expected to register a CAGR of around 15%. Developed countries, such as the United States, Germany, United Kingdom, and Japan are expected to register robust growth.

Rising Incidence of Hodgkin's Lymphoma

According to the American Cancer Society, estimates for Hodgkin's disease in the United States for 2017 were about 8,260 new cases (3,610 women and 4,650 men), and about 1,070 deaths (440 women and 630 men) from this cancer. Such an increase in number of new cases diagnosed every year, has been driving the Hodgkin's lymphoma treatment market. The Lymphoma Research Foundation is spreading awareness on lymphoma, and is also funding the research and development required to eradicate lymphoma.

Adverse Long-term Side-effects of Treatment

The treatment of Hodgkin's lymphoma is associated with physical side-effects. People who received treatment for Hodgkin's lymphoma have an increased risk of developing other diseases and conditions later. The side-effects can also result from cancer therapy, as radiation therapy and chemotherapy can cause permanent damage in patients. For instance, radiation therapy to the pelvic area can cause infertility, unless the ovaries or testicles are shielded during treatment. Some people have a higher risk of developing secondary cancer, especially myeloid leukemia, lung cancer, or breast cancer. Radiation therapy to the neck area can cause problems in thyroid gland, most commonly, hypothyroidism. Chemotherapy can result in suppressed blood cell formation, leading to anemia. Chemotherapy drugs kill cancer cells, but they could result in damage of normal cells as well. Several chemotherapy drugs, particularly anthracyclines, can cause heart damage, which may increase the risk of heart failure, over time. In the developing countries, reimbursement is low, which may hinder the growth of the market.

North America to Dominate the Market

The Hodgkin's Lymphoma treatment market has been segmented by treatment type and geography. By geography, it has been segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

Due to the presence of well-established healthcare facilities, North America dominates the Hodgkin's Lymphoma treatment market. However, the Asia-Pacific segment is expected to register the highest CAGR over the forecast period, as government and private firms are making significant investments on the healthcare industry. Over the last couple of years, there have several mergers, acquisitions, and collaborations between companies, to invest in the Japanese market.

Key Developments in the Market

October 2017 - FDA approved the second gene altering therapy Yescarta for the cancer. The therapy was approved for blood cancer and non-Hodgkin's lymphoma.

September 2017 - Aliqopa was approved by FDA, for the treatment of lymphoma.


Reasons to Purchase This Report

Analysis of the global Hodgkin's Lymphoma treatment market, with region-specific assessments and competition analysis on global and regional scales

Analyzing various perspectives of the industry with the help of Porter's five forces analysis

The treatment type that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support along with the Market Estimate sheet (in excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threats of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Increase Awareness About Hodgkin's Lymphoma
    • 6.1.2 Rising Incidence of Hodgkin's Lymphoma
    • 6.1.3 High Unmet Need in Older Patients and Patients with Relapsed or Refractory (R/R) Hl
  • 6.2 Market Restraints
    • 6.2.1 Adverse Long-Term Side Effects
    • 6.2.2 High Cost of Treatment
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Treatment Type
    • 7.1.1 Radiotherapy
    • 7.1.2 Chemotherapy
    • 7.1.3 Steroids
  • 7.2 By Geography
    • 7.2.1 North America
      • US
      • Canada
      • Mexico
    • 7.2.2 Europe
      • France
      • Germany
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • 7.2.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 7.2.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
      • South America
      • Brazil
      • Argentina
      • Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations & Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Bristol Myers Squibb Co.
  • 9.2 F. Hoffmann-La Roche Ltd
  • 9.3 Merck & Co. Inc.
  • 9.4 Pfizer Inc.
  • 9.5 4Sc Ag
  • 9.6 Actinium Pharmaceuticals Inc.
  • 9.7 Affimed Therapeutics AG
  • 9.8 Incyte Corp.
  • 9.9 Novartis AG

10. Future of the Market

Back to Top